Diana Morlote
Overview
Explore the profile of Diana Morlote including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
172
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ravindran A, Goyal G, Morlote D, Mackinnon A
Blood Res
. 2025 Feb;
60(1):13.
PMID: 40019725
No abstract available.
2.
Friedman J, Durham B, Reiner A, Yabe M, Petrova-Drus K, Dogan A, et al.
Br J Haematol
. 2024 Apr;
205(1):127-137.
PMID: 38613141
Histiocytic neoplasms are diverse clonal haematopoietic disorders, and clinical disease is mediated by tumorous infiltration as well as uncontrolled systemic inflammation. Individual subtypes include Langerhans cell histiocytosis (LCH), Rosai-Dorfman-Destombes disease...
3.
Clinical characteristics, molecular aberrations, treatments, and outcomes of malignant histiocytosis
Ruan G, Zanwar S, Ravindran A, Schram S, Abeykoon J, Hazim A, et al.
Am J Hematol
. 2024 Feb;
99(5):871-879.
PMID: 38409747
Malignant histiocytosis (MH) is an extremely rare neoplasm of the macrophage-dendritic cell lineage. We report the clinical characteristics, molecular aberrations, treatments, and outcomes of patients with MH seen at two...
4.
Dunn-Valadez S, Bathini S, Purdy K, Bachiashvili K, Bhatia R, Jamy O, et al.
Leuk Lymphoma
. 2023 Jul;
64(10):1673-1680.
PMID: 37493540
Significant variations exist related to the end of induction practices in the management of Acute Promyelocytic Leukemia (APL). These variations include all-trans retinoic acid (ATRA)-arsenic trioxide (ATO) in fixed doses...
5.
Goyal G, Parikh R, Richman J, Abeykoon J, Morlote D, Go R, et al.
Leuk Res
. 2023 Feb;
126:107032.
PMID: 36758375
With the advent of targeted therapeutics in Langerhans cell histiocytosis (LCH), there is a growing survivor population that might be at risk for late mortality from non-LCH causes, including second...
6.
Hanbazazh M, Morlote D, Mackinnon A, Harada S
Clin Lab Med
. 2022 Sep;
42(3):385-394.
PMID: 36150818
Molecular testing is now considered the standard of care to screen for disease, confirm the diagnosis, guide management, and use target therapy. Currently, several testing strategies are being used. One...
7.
Zanwar S, Abeykoon J, Dasari S, Ravindran A, Young J, Acosta-Medina A, et al.
Blood Cancer J
. 2022 Jun;
12(6):97.
PMID: 35764604
No abstract available.
8.
Dunn-Valadez S, Bathini S, Elston C, Rangaraju S, Di Stasi A, Worth S, et al.
Cancer Treat Res Commun
. 2022 Apr;
31:100560.
PMID: 35460975
Ivosidenib is an oral inhibitor of mutant Isocitrate dehydrogenase 1 (IDH1). It is approved for treatment of patients with relapsed or refractory IDH1-mutated acute myeloid leukemia (AML) and patients with...
9.
Pena M, Morlote D, Prieto Granada C
J Cutan Pathol
. 2021 Oct;
49(2):196-199.
PMID: 34643284
No abstract available.
10.
Hanbazazh M, Harada S, Reddy V, Mackinnon A, Harbi D, Morlote D
Am J Clin Pathol
. 2021 Jun;
156(5):728-748.
PMID: 34155503
Objectives: To provide an overview of the challenges encountered during the interpretation of sequence variants detected by next-generation sequencing (NGS) in myeloid neoplasms, as well as the limitations of the...